Donaldson Company reported earnings on August 26 with the most extreme options hedging the stock has seen in a year — and that positioning has now resolved, leaving behind a cleaner picture than the pre-print anxiety suggested.
The options story dominated the lead-up to results, and the data confirms just how charged the setup was. The put/call ratio reached 5.73 on August 25 — a new 52-week high, up from 4.93 the day before, and more than three standard deviations above its 20-day average of 0.98. That compares to the 3.14 reading flagged in the last earnings-eve note, which itself was described as exceptional. The PCR has now more than tripled again in two sessions. Put demand of this magnitude, on a name where the ratio spent most of July below 0.33, points to aggressive hedging by investors who had no interest in carrying unprotected exposure into the print. The stock closed at $93.26, down less than 1% on the week, which suggests the price action itself didn't particularly alarm anyone — the options market was simply doing its job.
Short interest tells a sharply different story, and the contrast is now starker than at any point in the past month. Bears have continued their retreat in force: SI dropped 17% in a single session on August 25 to 2.2% of the free float, extending a multi-week unwind that has shed nearly 40% of short positions since late July. The previous notes traced this trend from 4.1% in mid-August — the direction has been consistent and is now confirmed. Borrow conditions remain completely unthreatening. Availability has loosened dramatically to 2,583%, well above even the mid-July readings, with borrowing costs at 0.51% — cheap by any measure, and a fraction of where they'd need to be to signal any squeeze dynamics. The borrow market is not corroborating the put activity at all.
On the Street, Baird is the most recent mover worth noting. On August 19, Richard Eastman raised his price target to $105 from $95 while keeping an Outperform rating — the first upward revision after a string of cuts earlier in the year from $110 down to $95. The mean analyst target now sits at $97.80, roughly 5% above the current price, a modest premium that reflects a divided field. Morgan Stanley holds an Equal-Weight at $91, while Jefferies maintains a Buy at $123 — a target that looks stretched relative to the current valuation but reflects the bull case around Life Sciences growth. At a trailing P/E near 20x and EV/EBITDA of around 14x (both off their 30-day highs), valuation is not cheap for an industrial machinery name, but it's not elevated enough to be the defining concern. The 93rd-percentile EPS momentum score over 30 days is a meaningful positive signal — the earnings revision trend has been running hot even if forward growth expectations at 33rd percentile remain modest.
Peer performance adds context to the week's slight softness. ITT fell 5.4% and GTES dropped 4.3% on the week, making DCI's flat performance look relatively resilient within the industrial cohort. TWI was the notable outlier, up nearly 12%, though it has low correlation to DCI's filtration-driven model.
The next data point to monitor is how the stock price responds in the coming sessions now that the earnings event has passed — specifically whether the short-interest unwind continues, or whether bears use any post-print weakness as an opportunity to rebuild positions.
See the live data behind this article on ORTEX.
Open DCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
